November 16, 2006
CONTACT: Olivia Fermano
World’s First Collaborative
Lung Cancer Registry
(Philadelphia, PA) — Despite the many advances that have been made
over the past 30 years in the prevention, detection, and treatment of
cancer, one grim fact remains: the overall five-year lung cancer survival
rate is only 15%. The Abramson Cancer Center of the University
of Pennsylvania has joined an international effort launched by
Roswell Park Cancer Institute to potentially revolutionize the prevention
and management of this disease.
Precancerous lesions for lung cancer, which previously have been undetectable,
can now be visualized using technologies such as autofluorescence bronchoscopy
(AFB). Understanding how precancerous conditions become cancerous has
been difficult because no single institution was able to gather data from
enough patients or to follow up patients for a sufficient period of time
to provide clinically relevant answers. To resolve these issues, principal
investigators from the 11 centers have agreed to contribute patient information
to this multi-institutional, high-risk lung cancer patient registry.
The Abramson Cancer Center of the University of Pennsylvania was
established in 1973 as a center of excellence in cancer research, patient
care, education, and outreach. It is one of a select group of only 39
NCI-designated Comprehensive Cancer Centers in the United States and is
one of the top five in National Cancer Institute (NCI) funding. Home to
one of the largest clinical and research programs in the world, the Abramson
Cancer Center of the University of Pennsylvania has 300 active cancer
researchers and 300 full-time Penn physicians involved in cancer prevention,
diagnosis, and treatment. For more information about specific types of
cancer, cancer treatment, clinical trials, and research advances, visit
the Abramson Cancer Center’s resource on www.penncancer.org
or OncoLink at www.oncolink.org.
RPCI is a leader of past cancer breakthroughs, including the first use of chemotherapy, the PSA test for prostate cancer, and photodynamic therapy. RPCI also has significantly contributed to the field of smoking-related cancer research. The Institute’s cancer registry expertise began with the establishment of the international Gilda Radner Familial Ovarian Cancer Registry in 1981—a database of information on over 1,800 families from across the world with familial ovarian cancer.
PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.